Barinthus Biotherapeutics reports Q3 EPS (21c), consensus (44c)

Reports Q3 revenue $14.969M. “We continue our strong execution on our clinical trials, completing enrollment in the HBV003 trial of VTP-300 in chronic hepatitis B, and advancing VTP-1000 in celiac disease into the clinic with the first in human study of the novel SNAP-TI platform,” said Dr. Leon Hooftman, Chief Medical Officer of Barinthus Bio. “We expect a data rich fourth quarter from the VTP-300 chronic hepatitis B program, with updated interim readouts from both the HBV003 and IM-PROVE II trials accepted as late-breaking abstracts at the American Association for the Study of Liver Diseases – The Liver Meeting 2024. These updates will provide more mature data than previously disclosed as participants progress and move towards a potential functional cure.